微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 18.75% | -31.67% | -22.25% | 132/159 | 31.52% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 24.11% | -18.33% | 2.63% | 131/159 | 51.8% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 23.5% | -19.23% | -6.13% | 134/159 | 22.98% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 25.03% | -15.94% | -8.77% | 132/159 | 33.39% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 27.44% | -12.57% | -7.07% | 124/159 | 51.73% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 29.52% | 8.73% | 1.49% | 122/159 | 51.53% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 29.09% | 11.78% | -2.3% | 123/159 | 32.76% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 29.78% | 14.52% | -5.11% | 123/159 | 38.65% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 31.38% | 14.76% | 15.57% | 117/159 | 52.91% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 27.15% | 0.43% | 4.34% | 129/159 | 53.74% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 26.02% | -7.21% | 0.09% | 125/159 | 6.69% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 26% | -11.22% | -4.91% | 131/159 | 21.74% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 27.34% | -5.95% | 1.14% | 119/159 | 54.47% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 27.04% | -10.52% | -3.6% | 134/159 | 55.21% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 28.05% | -3.31% | -4.24% | 119/159 | 47.01% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 29.29% | 4.38% | 0.73% | 127/159 | 47.45% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 29.08% | 2.59% | -3.77% | 109/159 | 54.21% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 30.22% | -9.64% | 4.17% | 129/159 | -144.37% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 29.01% | -8.42% | 3.38% | 107/159 | 56.57% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 28.06% | -11.01% | -1% | 118/159 | 54.32% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 28.34% | -12.07% | -15.24% | 101/159 | 55.5% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 33.44% | 10.98% | 5.58% | 113/159 | -1213.38% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 31.67% | 13.41% | 0.46% | 95/159 | 55.47% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 31.53% | 13.18% | -2.18% | 101/159 | 55.47% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 32.23% | 12.88% | 6.97% | 90/159 | 51.37% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 30.13% | 7.3% | 7.89% | 116/159 | -205.91% | 微芯生物 | 96.27% | 行业排名> |
| 2018-09-30 | 27.93% | 2.98% | 0.26% | 93/159 | 54.25% | 贝达药业 | 95.47% | 行业排名> |
| 2018-06-30 | 27.86% | 1.43% | -2.44% | 97/159 | 53.68% | 贝达药业 | 95.51% | 行业排名> |
| 2018-03-31 | 28.56% | 5.85% | 1.68% | 91/159 | 54.19% | 贝达药业 | 95.54% | 行业排名> |
| 2017-12-31 | 28.08% | 12.59% | 3.55% | 108/159 | 52.58% | 贝达药业 | 95.74% | 行业排名> |
| 2017-09-30 | 27.12% | 12.23% | -1.26% | 85/159 | 49.32% | 退市金泰 | 96.19% | 行业排名> |
| 2017-06-30 | 27.46% | 19.9% | 1.81% | 85/159 | 48.02% | 贝达药业 | 95.81% | 行业排名> |
| 2017-03-31 | 26.98% | 10.51% | 8.16% | 71/159 | 46.89% | 退市金泰 | 95.93% | 行业排名> |
| 2016-12-31 | 24.94% | 7.23% | 3.21% | 100/159 | 48.44% | 贝达药业 | 95.58% | 行业排名> |
| 2016-09-30 | 24.17% | 8.25% | 5.49% | 72/159 | 45.76% | 贝达药业 | 95.89% | 行业排名> |
| 2016-06-30 | 22.91% | 6.64% | -6.16% | 83/159 | 46.2% | 微芯生物 | 97.46% | 行业排名> |
| 2016-03-31 | 24.41% | 6.02% | 4.95% | 67/159 | 43.5% | 贝达药业 | 97.01% | 行业排名> |
| 2015-12-31 | 23.26% | 13.63% | 4.19% | 92/159 | 46.24% | 贝达药业 | 97.02% | 行业排名> |
| 2015-09-30 | 22.32% | 12.67% | 3.92% | 68/159 | 44.69% | 舒泰神 | 94.38% | 行业排名> |
| 2015-06-30 | 21.48% | 17.8% | -6.71% | 74/159 | 45.36% | 贝达药业 | 96.95% | 行业排名> |
| 2015-03-31 | 23.03% | 23.79% | 12.48% | 64/159 | 43.46% | 舒泰神 | 94.4% | 行业排名> |